4-羧基-2-氯苯硼酸 | 851335-09-6

• 物质功能分类: 无机化工 - 无机盐 - 硼化物、硼酸盐和过硼酸盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-羧基-2-氯苯硼酸
• 中文别名: 4-羧基-2-氯苯基硼酸；2-氯-4-羧基苯硼酸
• 英文名称: 4-borono-3-chlorobenzoic acid
• 英文别名: 4-carboxy-2-chlorophenylboronic acid
• CAS: 851335-09-6
• 化学式: C₇H₆BClO₄
• mdl: MFCD07363763
• 分子量: 200.386
• InChiKey: FYDHSNLXZRGWFU-UHFFFAOYSA-N

物化性质

• 熔点：
  208-210
• 沸点：
  429.7±55.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.67
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT, KEEP COLD
• 危险品标志：
  Xi
• 安全说明：
  S26,S39
• 危险类别码：
  R41
• 海关编码：
  2931900090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持冷静

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Carboxy-2-chlorophenylboronic acid
Product Name:
Synonyms: 4-Borono-3-chlorobenzoic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Carboxy-2-chlorophenylboronic acid
Ingredient name:
CAS number: 851335-09-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BClO4
Molecular weight: 200.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

4-羧基-2-氯苯硼酸是一种医药中间体，可用于进行Suzuki偶联反应。有文献报道其可用于制备CRF受体拮抗剂以及LXR和FXR调节剂。

用途

4-羧基-2-氯苯硼酸用作科研试剂，广泛应用于实验室研发等场合。

反应信息

• 作为反应物：
  描述：

  4-羧基-2-氯苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride aluminum (III) chloride 、 potassium carbonate 作用下， 以 二氯甲烷 、 DEGME 、 水 为溶剂， 反应 3.0h， 生成 3-氯-4-(6-羟基喹啉-2-基)苯甲酸
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS AROMATIQUES BICYCLIQUES SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE

  摘要：

  本发明涉及一类新颖的取代双环芳族化合物，该化合物可用作S-硝基谷胱甘肽还原酶（GSNOR）的抑制剂，包括含有此类化合物的药物组合物，以及制造和使用这些化合物的方法。

  公开号：

  WO2012083165A1
• 作为试剂：
  描述：

  4-羧基-2-氯苯硼酸 、 2-氯-6-甲氧基喹啉 在 4-羧基-2-氯苯硼酸 作用下， 以46的产率得到3-chloro-4-(6-methoxyquinolin-2-yl)benzoic acid
  参考文献：
  名称：

  [EN] NOVEL SUBSTITUTED QUINOLINE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS
  [FR] NOUVEAUX COMPOSÉS QUINOLÉINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE S-NITROSOGLUTATHIONE RÉDUCTASE

  摘要：

  本发明涉及一种新型的喹啉化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这种化合物的制药组合物以及使用它们的方法。

  公开号：

  WO2012048181A1

文献信息

• Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries
  作者：Lanlan Jing、Gaochan Wu、Xia Hao、Fisayo A. Olotu、Dongwei Kang、Chin Ho Chen、Kuo-Hsiung Lee、Mahmoud E.S. Soliman、Xinyong Liu、Yuning Song、Peng Zhan

  DOI：10.1016/j.ejmech.2019.111696

  日期：2019.12

  chemistry synthesis via CuAAC reaction followed by in situ biological screening were used to discover selective Cdc25 inhibitors. The bioassay results showed that compound M2N12 proved to be the most potent Cdc25 inhibitor, which also act as a highly selective Cdc25C inhibitor and was about 9-fold potent than that of NSC 663284. Moreover, M2N12 showed remarkable anti-growth activity against the KB-VIN cell

  细胞分裂周期25（Cdc25）蛋白磷酸酶在细胞周期阶段之间的过渡中起着关键作用，其与各种癌症的关联已得到广泛证明，这使其成为抗癌治疗的理想靶标。尽管已经开发了几种Cdc25抑制剂，但大多数都显示出较低的活性和较差的亚型选择性。因此，发现对Cdc25亚型具有有效活性和显着选择性的新型小分子抑制剂非常重要，它不仅可以作为治疗癌症的药物，而且可以探索其在过渡过程中的作用机理。在这项研究中，通过CuAAC反应进行的微型平行点击化学合成，然后进行原位生物筛选，用于发现选择性的Cdc25抑制剂。生物测定结果表明，化合物M2N12被证明是最有效的Cdc25抑制剂，它也具有高选择性Cdc25C抑制剂的作用，其效力是NSC 663284的9倍。此外，M2N12对KB表现出显着的抗生长活性。 -VIN细胞系，与PXL和NSC 663284等效。采用全原子分子动力学（MD）模拟方法来探究M2N12对Cdc25C
• [EN] PYRIMIDINE CYCLOHEXENYL GLUCOCORTICOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RÉCEPTEURS DE GLUCOCORTICOÏDES DE TYPE PYRIMIDINE CYCLOHEXÉNYLE
  申请人：CORCEPT THERAPEUTICS INC

  公开号：WO2019236487A1

  公开（公告）日：2019-12-12

  The present invention provides a class of pyrimidinedione cyclohekenyl compounds and methods of using these compounds as glucocorticoid receptor modulators.

  本发明提供了一类吡啶二酮环己烯化合物以及将这些化合物用作糖皮质激素受体调节剂的方法。
• Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors
  作者：Peiyuan Zheng、Jian Zhang、Hui Ma、Xinrui Yuan、Pan Chen、Jinpei Zhou、Huibin Zhang

  DOI：10.1016/j.bmc.2019.02.045

  日期：2019.4

  compound 27 and 29 exhibited robust potency of BRD9 inhibition with IC50 values of 35 and 103 nM respectively. Docking studies were performed to explain the structure-activity relationship. Furthermore, compound 27 potently inhibited cell proliferation in cell lines A549 and EOL-1 with an IC50 value of 6.12 μM and 1.76 μM respectively. The chemical probe, compound 27, was identified that should prove to

  BRD9是哺乳动物SWI / SNF染色质重塑复合物（BAF）的亚基。在近20％的人类癌症中发现了SWI / SNF复合体突变。BRD9溴结构域发挥的生物学作用仍然知之甚少，因此必须确定有效且高度选择性的抑制剂以有效探索单个溴结构域蛋白的生物学特性。在本文中，我们合成了一系列咪唑并[1,5-a]吡嗪-8（7H）-one衍生物作为有效的BRD9抑制剂，并评估了其对体外BRD9的抑制活性以及对肿瘤细胞的抗增殖作用。令人欣慰的是，化合物27和29表现出强大的BRD9抑制能力，IC50值分别为35和103 nM。进行了对接研究以解释结构-活性关系。此外，化合物27有效抑制细胞系A549和EOL-1中的细胞增殖，IC50值分别为6.12μM和1.76μM。确定了化学探针化合物27，该探针在体外和体内环境中应被证明可用于进一步探索BRD9溴结构域生物学。
• C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors
  作者：Zheng Liu、Jacob J. Swidorski、Beata Nowicka-Sans、Brian Terry、Tricia Protack、Zeyu Lin、Himadri Samanta、Sharon Zhang、Zhufang Li、Dawn D. Parker、Sandhya Rahematpura、Susan Jenkins、Brett R. Beno、Mark Krystal、Nicholas A. Meanwell、Ira B. Dicker、Alicia Regueiro-Ren

  DOI：10.1016/j.bmc.2016.03.001

  日期：2016.4

  A series of C-3 phenyl- and heterocycle-substituted derivatives of C-3 deoxybetulinic acid and C-3 deoxybetulin was designed and synthesized as HIV-1 maturation inhibitors (MIs) and evaluated for their antiviral activity and cytotoxicity in cell culture. A 4-subsituted benzoic acid moiety was identified as an advantageous replacement for the 3′3′-dimethylsuccinate moiety present in previously disclosed

  设计并合成了一系列C-3脱氧贝丁酸和C-3脱氧贝丁酸的C-3苯基和杂环取代衍生物，作为HIV-1成熟抑制剂（MIs），并评估了它们在细胞培养中的抗病毒活性和细胞毒性。鉴定出4-取代的苯甲酸部分是先前公开的MI中存在的3'3'-二甲基琥珀酸酯部分的有利替代物，其阐明了药效团的拓扑学的新方面。与原型HIV-1 MI bevirimat（1，BVM）相比，新的类似物对野生型（wt）病毒具有出色的体外抗病毒活性，并且血清转移降低，这是临床研究中第一个评估的MI。化合物9a对wt病毒表现出与1类似的细胞培养能力（ 对于9a， WT EC 50 = 16 nM，而对于1a，则为10 nM ）。但是，9a的效力受人血清的影响较小，而该化合物在大鼠中的药代动力学特征与1相似。因此，9a（脱氧贝丁酸的4-苯甲酸衍生物）代表了探索第二代MI设计的新起点。
• [EN] SOLID FORMS OF AN S-NITROSOGLUTATHIONE REDUCTASE INHIBITOR<br/>[FR] FORMES SOLIDES D'UN INHIBITEUR DE S-NITROSOGLUTATHIONE RÉDUCTASE
  申请人：NIVALIS THERAPEUTICS INC

  公开号：WO2017044766A1

  公开（公告）日：2017-03-16

  The present invention provides solid forms and compositions thereof, which are useful as an inhibitor of S-nitrosoglutathione reductase and which exhibit desirable characteristics for the same.

  本发明提供了固体形态及其组合物，它们可用作S-亚硝基谷胱甘肽还原酶的抑制剂，并展现出对此目的所需的有益特性。